Perspective
Our work in Perspective
-
Even if it Survives the Courts, ObamaCare Needs Help
In an op-ed for The Hill, Schaeffer Center professor John Romley and Cedars-Sinai president and CEO Thomas Priselac write that step one to fix the ACA is accepting that payment cuts and cost shaming do not work.
Categorized in -
Reducing Unfair Out-of-Network Billing — Integrated Approaches to Protecting Patients
It may be possible to balance the competing goals of consumer protection and market innovation in state and federal oversight of health plan networks, according to a new opinion piece in The New England Journal of Medicine.
Categorized in -
The U.S. Should Assess the Economic Value of Drugs Rather Than Leave it up to Other Countries
Why are prescription drugs are often priced lower overseas? Many countries perform detailed assessments of the economic value of drugs and their benefits, and this could work in the U.S., says William Padula
Categorized in -
Texas Ruling Over Obamacare is Wrong to Claim That Without the Insurance Mandate, the Healthcare Law Can’t Survive
The Affordable Care Act’s insurance markets are stable, even without a penalty for those who don’t have coverage.
Categorized in -
The Trump Administration Side-Stepped Rulemaking Processes on the ACA’s State Innovation Waivers— And it Could Make Their New Section 1332 Guidance Invalid
Claims that the guidance is procedurally invalid open up potential new avenues for litigation surrounding section 1332 in general and could also become relevant to challenges regarding an approved waiver.
Categorized in -
Most Hospitals Receive Failing Score in at Least One Quality Dimension of Their Community Health Needs Assessment
Developing clearer guidelines for measuring a hospital’s orientation toward population health would be a big step towards fundamentally improving population health and changing the relationship between a hospital and its community.
Categorized in -
Mortality Risk, Insurance, and the Value of Life
People with shorter life expectancies place more value on increases in survival than people who anticipate longer life spans.
Categorized in -
The Bigger Message Behind Amgen’s Decision to Slash Cost of its Repatha Cholesterol Drug
Drug companies look to haggle less and sell more, and that could cost Express Scripts, CVS Health and UnitedHealth writes Goldman in MarketWatch.
Categorized in -
PODCAST: The Healthcare Issues Voters Care About in the 2018 Midterms
Fellow Matthew Fiedler reviews the Trump administration’s changes to the ACA, Medicaid expansion and how often candidates are talking about health policy.
Categorized in -
Analyzing Senator Hassan’s Binding Arbitration Approach To Preventing Surprise Medical Bills
Following the introduction of the “No More Surprise Medical Bills Act of 2018,” USC-Brookings Schaeffer Initiative for Health Policy experts analyze what the legislation could mean for patients if signed into law.
Categorized in